
Despina Sitara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4711106/publications.pdf Version: 2024-02-01



NESDINA SITADA

#	Article	IF	CITATIONS
1	C-FCF23 peptide alleviates hypoferremia during acute inflammation. Haematologica, 2021, 106, 391-403.	3.5	19
2	Correcting \hat{I}^2 -thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood, 2020, 136, 1968-1979.	1.4	33
3	Animal Models of Phosphorus Homeostasis. Current Molecular Biology Reports, 2019, 5, 34-47.	1.6	3
4	Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 304-310.	2.0	23
5	Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB Journal, 2018, 32, 3752-3764.	0.5	85
6	FGF-23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis. Journal of Biological Chemistry, 2014, 289, 9795-9810.	3.4	114
7	Klotho Deficiency Disrupts Hematopoietic Stem Cell Development and Erythropoiesis. American Journal of Pathology, 2014, 184, 827-841.	3.8	49
8	Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone. PLoS Genetics, 2008, 4, e1000154.	3.5	159
9	Correlation among Hyperphosphatemia, Type II Sodium Phosphate Transporter Activity, and Vitamin D Metabolism in Fgf-23 Null Mice. Annals of the New York Academy of Sciences, 2007, 1116, 485-493.	3.8	4
10	Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null Animals. American Journal of Pathology, 2006, 169, 2161-2170.	3.8	139
11	Premature agingâ€like phenotype in fibroblast growth factor 23 null mice is a vitamin Dâ€mediated process. FASEB Journal, 2006, 20, 720-722.	0.5	327
12	Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biology, 2004, 23, 421-432.	3.6	481